Lawsuit filed for Investors who lost money with shares of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX)

An investor, who purchased shares of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), filed a lawsuit over alleged violations of Federal Securities Laws by Aldeyra Therapeutics, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) have certain options and for certain investors are short and strict deadlines running. Deadline: September 29, 2023. NASDAQ: ALDX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Lexington, MA based Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases.

In December 2022, Aldeyra Therapeutics, Inc. submitted a new drug application ("NDA") to the U.S. Food and Drug Administration ("FDA") for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma (the "ADX-2191 NDA").

On June 21, 2023, Aldeyra Therapeutics, Inc. issued a press release "announc[ing] receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the 505(b)(2) New Drug Application (NDA) of ADX-2191 (methotrexate for injection, USP), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma (PVRL)." The press release stated that "[a]lthough no safety or manufacturing issues with ADX-2191 were identified, the FDA stated that there was a 'lack of substantial evidence of effectiveness' due to 'a lack of adequate and well-controlled investigations' in the literature-based NDA submission."

Shares of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) declined from $11.94 per share on June 09, 2023, to as low as $5.47 per share on June 21, 2023.

The plaintiff claims that between March 17, 2022 and June 20, 2023, the Defendants made false and/or misleading statements and/or failed to disclose that the ADX-2191 NDA did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191's effectiveness, that as a result, the FDA was unlikely to approve the ADX-2191 NDA in its current form, that accordingly, the Company had overstated ADX-2191's clinical and/or commercial prospects, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.